PDL BioPharma (PDLI) - Depomed paying off

09:36 EDT 10 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - PDL BioPharma: PDL BioPharma recently reported strong Q217 earnings mainly due to royalties related to the authorized generic of Glumetza as well as an increase in the fair value of the Depomed royalty assets as a whole. Also, LENSAR, which became a wholly-owned subsidiary on 11 May, was consolidated in the results, with $2.6m in revenues and $3.8m in expenses. The company continues to receive royalty payments for Tysabri for longer than expected; it was paid $16.3m in Q217.
ISIN: US69329Y1047

Original Article: PDL BioPharma (PDLI) - Depomed paying off


More From BioPortfolio on "PDL BioPharma (PDLI) - Depomed paying off"

Quick Search

Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...